Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Eliminate "Drug Lag" at Initiative of Politicians: Mr Sekiguchi
November 2, 2009
- DSP Completes Acquisition of Sepracor Inc.
November 2, 2009
- Astellas, IBL Discontinue Development of ASK8007 as Anti-RA Drug
November 2, 2009
- Pfizer Completes Acquisition of Wyeth
November 2, 2009
- Kyowa Kirin to Apply for KW-0761 Hopefully in 2011
November 2, 2009
- Roche to Strengthen Partnering in Japan: Mr McCracken
November 2, 2009
- REGULATORY NEWS IN BRIEF
November 2, 2009
- EP-Mint to Acquire Sogo SMO: EPS
November 2, 2009
- Lawmakers to Have Stronger Influence on Medical Fees
November 2, 2009
- Incretin Therapy Suitable for Japanese Patients with Diabetes: Dr Seino
October 26, 2009
- REGULATORY NEWS IN BRIEF
October 26, 2009
- Biogen Idec Japan Aims at 50% Share in Market for IFN-b
October 26, 2009
- Shionogi Allies with UK Universities, Bioventures for Drug Discovery
October 26, 2009
- Rasilez May Become Blockbuster: T. Rosenberg, Novartis
October 26, 2009
- Life Science Degrades to 2nd Place in Priority Science and Technology Ranking
October 26, 2009
- Datamonitor Predicts that Acquisition of Solvay Will Have Positive Effects on Abbott
October 26, 2009
- R＆D NEWS IN BRIEF
October 26, 2009
- Nat'l Univ. Hospitals Plans to Start Joint Purchasing in FY2010
October 26, 2009
- Hokkaido Univ. Hospital to Increase Direct Purchase of Drugs
October 26, 2009
- Cravit Remains No. 1 on Both HP, GP Markets: Rep Track Survey
October 26, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…